Background: Development of high avidity, broadly neutralizing antibodies (Abs) is a priority after vaccination against rapidly evolving, widely disseminated viruses like human norovirus. After vaccination with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in titer following a second vaccine dose. Methods: Blockade Ab relative avidity was evaluated by measuring the slope of blockade Ab neutralization curves. Results: Blockade Ab avidity to the GI.1 vaccine component peaked at day 35 (7 days after dose 2). Avidities to heterotypic genogroup I VLPs were not sustained at day 35 after vaccination or GI.1 infection, as measured from archived sera. Only secretor-positive participants maintained high avidity blockade Ab to GI.1 at day 180. Avidity to the GII.4c vaccine component peaked at day 7, remained elevated through day 180, and was not secretor dependent. Avidity to an immunologically novel GII.4 strain VLP correlated with preexisting Ab titer to an ancestral strain Epitope A. Conclusions: Host genetics and pre-exposure history shape norovirus vaccine Ab responses, including blockade Ab avidity. Avidity of potentially neutralizing Ab may be an important metric for evaluating vaccine responses to highly penetrant viruses with cross-reactive serotypes.
RCT Entities:
Background: Development of high avidity, broadly neutralizing antibodies (Abs) is a priority after vaccination against rapidly evolving, widely disseminated viruses like human norovirus. After vaccination with a multivalent GI.1 and GII.4c norovirus virus-like particle (VLP) vaccine candidate adjuvanted with alum and monophosphoryl lipid A (MPL), blockade Ab titers peaked early, with no increase in titer following a second vaccine dose. Methods: Blockade Ab relative avidity was evaluated by measuring the slope of blockade Ab neutralization curves. Results: Blockade Ab avidity to the GI.1 vaccine component peaked at day 35 (7 days after dose 2). Avidities to heterotypic genogroup I VLPs were not sustained at day 35 after vaccination or GI.1 infection, as measured from archived sera. Only secretor-positive participants maintained high avidity blockade Ab to GI.1 at day 180. Avidity to the GII.4c vaccine component peaked at day 7, remained elevated through day 180, and was not secretor dependent. Avidity to an immunologically novel GII.4 strain VLP correlated with preexisting Ab titer to an ancestral strain Epitope A. Conclusions: Host genetics and pre-exposure history shape norovirus vaccine Ab responses, including blockade Ab avidity. Avidity of potentially neutralizing Ab may be an important metric for evaluating vaccine responses to highly penetrant viruses with cross-reactive serotypes.
Authors: Kari Debbink; Lisa C Lindesmith; Eric F Donaldson; Veronica Costantini; Martina Beltramello; Davide Corti; Jesica Swanstrom; Antonio Lanzavecchia; Jan Vinjé; Ralph S Baric Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Amanda Reeck; Owen Kavanagh; Mary K Estes; Antone R Opekun; Mark A Gilger; David Y Graham; Robert L Atmar Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Melissa K Jones; Makiko Watanabe; Shu Zhu; Christina L Graves; Lisa R Keyes; Katrina R Grau; Mariam B Gonzalez-Hernandez; Nicole M Iovine; Christiane E Wobus; Jan Vinjé; Scott A Tibbetts; Shannon M Wallet; Stephanie M Karst Journal: Science Date: 2014-11-07 Impact factor: 47.728
Authors: Lisa C Lindesmith; Martina Beltramello; Eric F Donaldson; Davide Corti; Jesica Swanstrom; Kari Debbink; Antonio Lanzavecchia; Ralph S Baric Journal: PLoS Pathog Date: 2012-05-17 Impact factor: 6.823
Authors: Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Kari Debbink; Excel W Swann; Jan Vinjé; Ralph S Baric Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Mark R Zweigart; Samantha R May; Daniel Kelly; Rachel Williams; Sylvia Becker-Dreps; Filemón Bucardo; David J Allen; Judith Breuer; Ralph S Baric Journal: Viruses Date: 2022-06-14 Impact factor: 5.818
Authors: Lisa C Lindesmith; Jacob F Kocher; Eric F Donaldson; Kari Debbink; Michael L Mallory; Excel W Swann; Paul D Brewer-Jensen; Ralph S Baric Journal: J Infect Dis Date: 2017-12-05 Impact factor: 5.226
Authors: Lisa C Lindesmith; Jonathan R McDaniel; Anita Changela; Raffaello Verardi; Scott A Kerr; Veronica Costantini; Paul D Brewer-Jensen; Michael L Mallory; William N Voss; Daniel R Boutz; John J Blazeck; Gregory C Ippolito; Jan Vinje; Peter D Kwong; George Georgiou; Ralph S Baric Journal: Immunity Date: 2019-06-18 Impact factor: 31.745
Authors: Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Kara Jensen; Boyd L Yount; Veronica Costantini; Matthew H Collins; Caitlin E Edwards; Timothy P Sheahan; Jan Vinjé; Ralph S Baric Journal: Cell Mol Gastroenterol Hepatol Date: 2020-04-11
Authors: Mark R Zweigart; Sylvia Becker-Dreps; Filemón Bucardo; Fredman González; Ralph S Baric; Lisa C Lindesmith Journal: Viruses Date: 2021-10-09 Impact factor: 5.048
Authors: Lisa C Lindesmith; Paul D Brewer-Jensen; Michael L Mallory; Boyd Yount; Matthew H Collins; Kari Debbink; Rachel L Graham; Ralph S Baric Journal: J Virol Date: 2019-01-04 Impact factor: 5.103